How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Alimta Market
- By Indication: Non-Small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Breast Cancer, Gastroesophageal Cancer, Other Solid Tumors
- By Line of Therapy: First-Line Therapy, Second-Line Therapy, Maintenance Therapy, Adjuvant Therapy
- By Treatment Regimen: Monotherapy, Combination Therapy with Cisplatin, Combination Therapy with Carboplatin, Combination Therapy with Bevacizumab
- By Patient Demographics: Elderly Patients (65+), Adult Patients (18-64), Patients with Renal Impairment, Patients with ECOG Performance Status 0-1
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Non-Small Cell Lung Cancer (NSCLC) leads By Indication at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 274 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.164 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.172 →
Full report · locked preview
Everything inside the Alimta Market report
A complete, evidence-based study - 11 chapters and 115 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Indication 5
Line of Therapy 4
Treatment Regimen 4
Patient Demographics 4
Companies profiled
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd.
Mylan N.V. (now part of Viatris)
Cipla Limited
Sun Pharmaceutical Industries Ltd.
Hetero Drugs Limited
Zydus Cadila
Natco Pharma Limited
Fresenius Kabi
Sandoz (Novartis)
Dr. Reddy's Laboratories
Lupin Limited
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Teva Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Mylan N.V. (now part of Viatris)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Cipla Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Sun Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Hetero Drugs Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Zydus Cadila
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Natco Pharma Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Fresenius Kabi
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sandoz (Novartis)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Dr. Reddy's Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Lupin Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Aurobindo Pharma
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Torrent Pharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Macleods Pharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,527M by 2033 · 8.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Non-Small Cell Lung Cancer (NSCLC)57.4
- Malignant Pleural Mesothelioma8.5
- Breast Cancer9.9
- Gastroesophageal Cancer7.8
- Other Solid Tumors16.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$266.2M → $492.3M · 8.0%
Europe$185.5M → $313.4M · 6.8%
Asia Pacific$169.4M → $326.2M · 8.5%
Latin America$104.8M → $190.6M · 7.8%
Middle East and Africa$80.7M → $137.0M · 6.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.262026
8.262027
8.282028
8.302029
8.302030
8.312031
8.322032
8.342033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Eli Lilly and Company16.7
- Teva Pharmaceutical Industries Ltd.22.2
- Mylan N.V. (now part of Viatris)7.6
- Cipla Limited13.3
- Sun Pharmaceutical Industries Ltd.5.7
- Hetero Drugs Limited6.7
- Others27.8
Segment contribution to growth (%)
Fig. 18 · p.39 →Indication31.7%
Line of Therapy25.4%
Treatment Regimen18.1%
Patient Demographics24.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.7
- Europe21.5
- Asia Pacific22.4
- Latin America13.1
- Middle East and Africa9.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Eli Lilly and Company | 84 | 84 | 90 | 90 | 73 | 75 | 83 |
| Teva Pharmaceutical Industries Ltd. | 77 | 85 | 87 | 73 | 70 | 91 | 81 |
| Mylan N.V. (now part of Viatris) | 75 | 69 | 68 | 81 | 83 | 74 | 75 |
| Cipla Limited | 81 | 67 | 81 | 67 | 64 | 57 | 70 |
| Sun Pharmaceutical Industries Ltd. | 52 | 74 | 56 | 51 | 58 | 59 | 58 |
| Hetero Drugs Limited | 62 | 62 | 57 | 56 | 52 | 51 | 57 |
| Zydus Cadila | 44 | 52 | 65 | 41 | 49 | 62 | 52 |
| Natco Pharma Limited | 41 | 38 | 40 | 57 | 57 | 56 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V. (now part of Viatris)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | ✓ | ✓ | ✓ | ✓ | ◐ | − |
| Teva Pharmaceutical Industries Ltd. | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Mylan N.V. (now part of Viatris) | ◐ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Cipla Limited | ✓ | ◐ | ◐ | ✓ | − | − |
| Sun Pharmaceutical Industries Ltd. | − | ◐ | − | − | ◐ | ◐ |
| Hetero Drugs Limited | − | ◐ | − | ◐ | ◐ | ◐ |
| Zydus Cadila | − | ◐ | − | − | ◐ | − |
| Natco Pharma Limited | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Eli Lilly and Company83
2Teva Pharmaceutical Industries Ltd.81
3Mylan N.V. (now part of Viatris)75
4Cipla Limited70
5Sun Pharmaceutical Industries Ltd.58
6Hetero Drugs Limited57
7Zydus Cadila52
8Natco Pharma Limited48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Eli Lilly and CompanyTeva Pharmaceutical Industries Ltd.
Challenger2
Strong scale, closing on the leaders.
Mylan N.V. (now part of Viatris)Cipla Limited
Contender2
Focused players with pockets of strength.
Sun Pharmaceutical Industries Ltd.Hetero Drugs Limited
Niche2
Specialists in a single segment or region.
Zydus CadilaNatco Pharma Limited
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Indication in North America, then scale across Alimta Market — a $382M beachhead inside a $5.05B market.
Beachhead (SOM)$382Mobtainable near-term
Serviceable (SAM)$2.09Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Non-Small Cell Lung Cancer (NSCLC)
Best fit — highest urgency & budget in Indication.
Economic buyer77 fit
Malignant Pleural Mesothelioma
Strong fit — clear ROI and a fast path to value.
End user69 fit
Breast Cancer
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Indication in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Line of Therapy & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Treatment Regimen
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel29%
Digital / self-serve20%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Indication leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Alimta Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified25%
Evaluation12%
Closed-won6%
$20.3KCAC
$87KLTV
4.3:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Alimta Market is a durable-growth opportunity — $5.52B by 2033, compounding at 6.7%.
TAM · 2025$3.28Btoday
TAM · 2033$5.52Bforecast
CAGR6.7%2027–2033
Cumulative$38.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.52BTotal addressable market
SAM$1.96BServiceable available market
SOM$315MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.7% CAGR
Demand compounds through 2033, outpacing GDP across Indication.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Indication moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.52BLarge & growingTAM by 2033 at 6.7% CAGR
$1.96BServiceable nowreachable with today’s model
$315MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.31BBear4.4% CAGR
$5.52BBase6.7% CAGR
$7.07BBull8.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Line of Therapy optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Alimta Market — a $10.7B market by 2033. Plan: grow share from 7.9% to 14.2%.
Market size · 2033$10.7Btotal addressable
Market CAGR11.6%2027–2033
Target share14.2%from 7.9% today
Revenue ambition$1.51Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.9% | 14.2% | At risk |
| Revenue | $841M | $1.51B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 28.1% | 41.2% | On track |
| Customer retention | 86.5% | 96.7% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Indication
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Line of Therapy capability
A defensible second engine — invest in Line of Therapy to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Indication share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Line of Therapy
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $205M capacity & capability investment
- Greenlight bolt-on M&A in Line of Therapy
- Authorise North America expansion plan
- Fund R&D program for Indication leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Alimta Market conversation — a $3.95B market you can size, segment and defend in minutes.
Market size · 2033$3.95Btotal opportunity
Growth8.8%CAGR to 2033
Addressable buyers1,674+accounts in scope
Typical ROI4.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Indication
Goal Grow share in Indication
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.9×return on cost, year one
< 3 mopayback period
$75K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Eli Lilly and CompanyTeva Pharmaceutical Industries Ltd.Mylan N.V. (now part of Viatris)Cipla LimitedSun Pharmaceutical Industries Ltd.Hetero Drugs LimitedZydus CadilaNatco Pharma Limited+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Alimta Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Alimta Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Vincristine Sulfate Liposome Injection Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportTorsemide Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportInteractive Wound Dressing Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportInsulin Patch Pump Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportPreclinical CRO Treatment Market
Market size, share, segmentation and regional forecast.
$476M market · 2025 base year
View reportHysteroscopic Endometrial Resection Procedures Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View report3D Printed Drugs Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportLixisenatide Market
Market size, share, segmentation and regional forecast.
$785M market · 2025 base year
View reportMedical Finger Cots Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportDermal Filler and Botolinum Toxin Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportGlycosylated Hemoglobin and C Peptide Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportSickle Cell Disease Treatment Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.